Nukkleus Capex To Depreciation from 2010 to 2024
| NUKK Stock | USD 1.52 0.01 0.65% |
Capex To Depreciation | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.93781364 |
Check Nukkleus financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nukkleus' main balance sheet or income statement drivers, such as Depreciation And Amortization of 172 K, Selling General Administrative of 3.4 M or Selling And Marketing Expenses of 44.1 K, as well as many indicators such as Price To Sales Ratio of 45.05, Ptb Ratio of 51.21 or Capex To Depreciation of 0.0. Nukkleus financial statements analysis is a perfect complement when working with Nukkleus Valuation or Volatility modules.
Nukkleus | Capex To Depreciation |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Nukkleus Correlation against competitors. For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.36) | Revenue Per Share 7.024 | Quarterly Revenue Growth (0.97) | Return On Assets (1.15) | Return On Equity (7.42) |
The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.